Inflammatory biomarkers and atrial fibrillation: Potential role of inflammatory pathways in the pathogenesis of atrial fibrillation-induced thromboembolism

Current Vascular Pharmacology

Volumn 13, Issue 2, 2015, Pages 192-201

  Guo, Yutao ^a,b   Lip, Gregory Y H ^a   Apostolakis, Stavros ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Atrial fibrillation; Endothelial dysfunction; Inflammation; Platelet activation; Stroke; Virchow s triad

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN IB; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT;

ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING; BRAIN ISCHEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; ANIMAL; BLOOD; COMPLICATION; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STROKE; THROMBOCYTE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATRIAL FIBRILLATION; BIOMARKERS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEUROPROTECTIVE AGENTS; PLATELET ACTIVATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; STROKE; THROMBOEMBOLISM;

EID: 84929726303     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660165     Document Type: Article

References (137)

1. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-7
2. Banerjee A, Marín F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke 2011; 42: 3316-22
3. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-66
4. Roldán V, Marín F, Blann AD, et al.Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24: 1373-80
5. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin- 6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004; 93: 1368-73
6. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin- 6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-82
7. Marín F, Corral J, Roldán V, et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004; 37: 699-704
8. Conway DS, Lip GY. Atrial fibrillation, the prothrombotic state, inflammation, and gender. Am J Cardiol 2005; 95: 819
9. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin- 6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-67
10. Blann AD, Li-Saw-Hee F, Lip GY, et al. Increased membrane and soluble P-selectin in atrial fibrillation. Circulation 1999; 100: e86-7
11. Goldsmith IR, Foo LS, Blann AD, Lip GY. Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following percutaneous balloon mitral valvuloplasty. Clin Cardiol 2000; 23: 587-90
12. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001; 22: 1741-7
13. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106: 1962-7
14. Kamath S, Blann AD, Chin BS, et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J 2002; 23: 1788-95
15. Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40: 484-90
16. Kamath S, Blann AD, Chin BS, Lip GY. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart 2003; 89: 1093-5
17. Conway DS, Heeringa J, Van Der Kuip DA, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 2003; 34: 413-7
18. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5
19. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 2008; 51: 1790-3
20. Freestone B, Lip GY. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie 2008; 28: 207-12
21. Raviele A, Ronco F. Endothelial dysfunction and atrial fibrillation: what is the relationship? J Cardiovasc Electrophysiol 2011; 22: 383-4
22. Colkesen Y, Acil T, Abayli B, et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinol 2008; 19: 411-4
23. Hayashi M, Takeshita K, Inden Y, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128: e113-8
24. Herrera Siklódy C, Arentz T, Minners J, et al. Cellular damage, platelet activation, and inflammatory response after pulmonary vein isolation: a randomized study comparing radiofrequency ablation with cryoablation. Heart Rhythm 2012; 9: 189-96
25. Masawa N, Yoshida Y, Yamada T, Joshita T, Ooneda G. Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi. Virchows Arch A Pathol Anat Histopathol 1993; 422: 67-71
26. Shirani J, Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: Implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol 2000; 9: 95-101
27. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37: 1436-42
28. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 2003; 111: 137-42
29. Conway. Further insights into the prothrombotic state in mitral stenosis and atrial flutter. Chest 2004; 125: 2361-62
30. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009; 55: 229-38
31. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109: 2566-71
32. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20
33. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1002-7
34. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-33
35. Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 2000; 35: 1926-31
36. Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinol 2002; 13: 339-47
37. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106: 1962-7
38. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5
39. Roldán V, Marín F, García-Herola A, Lip GY. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/ dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 2005; 116: 321-5
40. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37: 2294-300
41. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43: 599-606
42. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011; 9: 275-81
43. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol 2012; 155: 217-22
44. Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57: 2496-504
45. Pinto A, Tuttolomondo A, Casuccio A, et al. Immunoinflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009; 116: 781-9
46. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol 2009; 215: 84-9
47. Tuttolomondo A, Pinto A, Corrao S, et al. Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis 2009; 203: 503-8
48. Tofler GH, Massaro J, Levy D, et al. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 2005; 96: 1280-3
49. Watson T, Arya A, Sulke N, Lip GY. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation. Chest 2010; 137: 869-76
50. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 2008; 112: 3555-62
51. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 2010; 8: 1689-701
52. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 2011; 589: 4115-23
53. Stoll G, Kleinschnitz C, Nieswandt B. The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development. Hamostaseologie 2010; 30: 136-8
54. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006; 107: 3537-45
55. Reininger AJ. vWF attributes--impact on thrombus formation. Thromb Res 2008; 122 Suppl 4: S9-13
56. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-30
57. Stoll G, Kleinschnitz C, Nieswandt B. Combating innate inflammation: a new paradigm for acute treatment of stroke? Ann N Y Acad Sci 2010; 1207: 149-54
58. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113: 3600-3
59. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Plasma betathromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J 1986; 27: 481-7
60. Kamath S, Chin BS, Blann AD, Lip GY. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinol 2002; 13: 627-36
61. Choudhury A, Freestone B, Patel J, Lip GY. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? Chest 2007; 132: 1913-9
62. Choudhury A, Chung I, Blann AD, Lip GY. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to pselectin and antithrombotic therapy. Chest 2007; 131: 809-15
63. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet Pselectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007; 49: 1957-64
64. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol 2008; 127: 135-7
65. Choudhury A, Chung I, Panja N, Patel J, Lip GY. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. Chest 2008; 134: 574-81
66. Osmancik P, Peroutka Z, Budera P, Herman D, Stros P, Straka Z. Changes in cytokine concentrations following successful ablation of atrial fibrillation. Eur Cytokine Netw 2010; 21: 278-84
67. Lip GY. The prothrombotic state in atrial fibrillation: the atrium, the endothelium and tissue factor? Thromb Res 2003; 111: 133-5
68. Ferro D, Loffredo L, Polimeni L, et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 2007; 27: 2763-8
69. Duygu H, Barisik V, Kurt H, Turk U, Ercan E, Kose S. Prognostic value of plasma soluble CD40 ligand in patients with chronic nonvalvular atrial fibrillation. Europace 2008; 10: 210-4
70. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38: 1229-37
71. Choudhury A, Chung I, Blann A, Lip GY. Platelet adhesion in atrial fibrillation. Thromb Res 2007; 120: 623-9
72. Kaski JC, Arrebola-Moreno AL. Inflammation and thrombosis in atrial fibrillation. Rev Esp Cardiol 2011; 64: 551-3
73. Hammwohner M, Ittenson A, Dierkes J, et al.Platelet expression of cd40/cd40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med (Maywood) 2007; 232: 581-9
74. Yacoub D, Hachem A, Theoret JF, Gillis MA, Mourad W, Merhi Y. Enhanced levels of soluble cd40 ligand exacerbate platelet aggregation and thrombus formation through a cd40-dependent tumor necrosis factor receptor-associated factor-2/rac1/p38 mitogenactivated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2424-33
75. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Thromb Haemost 2009; 102: 916-24
76. Henn V, Slupsky JR, Grafe M, et al.CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4
77. Power CA, Clemetson JM, Clemetson KJ, Wells TN. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 1995; 7: 479-82
78. Schäfer A, Schulz C, Eigenthaler M, et al. Novel role of the membrane- bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-12
79. Niewiarowski S, Walz DA, James P, Rucinski B, Kueppers F. Identification and separation of secreted platelet proteins by isoelectric focusing: evidence that low-affinity platelet factor 4 is converted to beta-thromboglobulin by limited proteolysis. Blood 1980; 55: 453-6
80. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev 2000; 177: 204-16
81. Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 1920-7
82. Conway DSG, Buggin P, Lip GYH. Relation of interleukin-6, Creactive protein, and the prothrombotic state to transesophgeal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004; 93: 1368-73
83. Cianfrocca C, Loricchio ML, Pelliccia F, et al. C-reactive protein and left atrial appendage velocity are independent determinants of the risk of thrombogenesis in patients with atrial fibrillation. Int J Cardiol 2010; 142: 22-8
84. Makita S, Nakamura M, Satoh K, et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis. 2009; 204: 234-8
85. Elkind MS, Luna JM, Moon YP, et al.High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 2009; 73: 1300-7
86. Maehama T, Okura H, Imai K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol 2010; 106: 535-8
87. Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol 2012; 109: 95-9
88. Thambidorai SK, Parakh K, Martin DO, et al. Relation of Creactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805-7
89. Maehama T, Okura H, Imai K, et al. Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation. J Cardiol 2010; 56: 118-24
90. Ederhy S, Di Angelantonio E, Dufaitre G, et al. C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. Int J Cardiol 2012; 159: 40-6
91. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin- 6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-7
92. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008; 155: 303-9
93. Leftheriotis DI, Fountoulaki KT, Flevari PG, et al.The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009; 135: 361-9
94. Burzotta F, Blann AD, Balakrishnan B, et al.Characterizations and validity of inflammatory biomarkers in the prediction of postoperative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010; 104: 122-7
95. Henningsen KM, Iacoviello L, Di Castelnuovo A, et al.Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001; 88: 1125-8
96. Conway DS, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 2009; 69: 425-32
97. Henningsen KM, Nilsson B, Bruunsgaard H, Chen X, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand Cardiovasc J 2009; 43: 285-91
98. Schnabel RB, Kerr KF, Lubitz SA, et al.Candidate Gene Association Resource (CARe) Atrial Fibrillation/Electrocardiography Working Group. Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) project. Circ Cardiovasc Genet 2011; 4: 557-64
99. Conway DSG, Buggin P, Hughes EA, Lip GYH. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-82
100. Roldán V, Marín F, Martínez JG, García-Herola A, Sogorb F, Lip GY. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005; 95: 881-2
101. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Inflammation in Ischemic Stroke Subtypes. Curr Pharm Des 2012; 18: 4289-310
102. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462-6
103. Whiteley W, Wardlaw J, Dennis M, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012; 43: 86-91
104. Aidoudi S, Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb Haemost 2010; 104: 941-8
105. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51
106. Nagao T, Hamamoto M, Kanda A, et al. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke 1995; 26: 1365-8
107. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-12
108. Atalar E, Haznedaroglu IC, Acil T, et al. Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia. Platelets 2003; 14: 407-11
109. Nozawa T, Inoue H, Iwasa A, et al. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 2004; 68: 29-34
110. Motoki H, Tomita T, Aizawa K, et al. Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period. Comparison with chronic atrial fibrillation. Circ J 2009; 73: 1403-7
111. Ohara K, Inoue H, Nozawa T, et al. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. Int J Cardiol 2008; 126: 316-21
112. de Winter RJ, Manten A, de Jong YP, Adams R, van Deventer SJ, Lie KI. Interleukin 8 released after acute myocardial infarction is mainly bound to erythrocytes. Heart 1997; 78: 598-602
113. Melenovsky V, Lip GY. Interleukin-8 and atrial fibrillation. Europace 2008; 10: 784-5
114. Scridon A, Morel E, Nonin-Babary E, Girerd N, Fernandez C, Chevalier P. Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace 2012; 14: 948-53
115. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A, Di Biase M. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Invest 2012; 42: 371-5
116. Liuba I, Ahlmroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008; 10: 848-53
117. Grau AJ, Reis A, Buggle F, et al. Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 2001; 192: 41-7
118. Domac FM, Misirli H. The role of neutrophils and interleukin-8 in acute ischemic stroke. Neurosciences (Riyadh) 2008; 13: 136-41
119. Ormstad H, Aass HC, Lund-Sørensen N, Amthor KF, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol 2011; 258: 677-85
120. Yamasaki Y, Matsuo Y, Matsuura N, Onodera H, Itoyama Y, Kogure K. Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. Stroke 1995; 26: 318-22
121. Garau A, Bertini R, Colotta F, et al. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005; 30: 125-31
122. Cavalieri B, Mosca M, Ramadori P, et al. Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric noncompetitive inhibitor of CXCL8 receptors: a therapeutic approach for the treatment of post-ischemic hepatic syndromes. Int J Immunopathol Pharmacol 2005; 18: 475-86
123. Villa P, Triulzi S, Cavalieri B, et al. The interleukin-8 (IL- 8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med 2007; 13: 125-33
124. Gu L, Tseng SC, Rollins BJ. Monocyte chemoattractant protein-1. Chem Immunol 1999; 72: 7-29
125. Cochran BH, Reffel AC, Stiles CD. Molecular cloning of gene sequences regulated by plaelet-derived growth factor. Cell 1983; 33: 939-47
126. Sheikine Y, Hansson GK. Chemokines and atherosclerisis. Ann Med 2004; 36: 98-118
127. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 1989; 142: 1956-62
128. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989; 244: 487-93
129. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-95
130. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-66
131. Canouï-Poitrine F, Luc G, Mallat Z, et al. PRIME Study Group. Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology 2011; 77: 1165-73
132. Tousoulis D, Zisimos K, Antoniades C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distension. Int J Cardio 2009; 136: 258-62
133. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardioembolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 2009; 101: 929-37
134. Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 2011; 100: 1029-36
135. Lind M, Boman K, Johansson L, Nilsson TK, Järvholm LS, Jansson JH. Von Willebrand factor predicts major bleeding and mortality during oral anticoagulant treatment. J Intern Med 2012; 271: 239-46
136. Gelderblom M, Weymar A, Bernreuther C, et al.Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood 2012; 120: 3793-802
137. Culman J, Nguyen-Ngoc M, Glatz T, Gohlke P, Herdegen T, Zhao Y. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial. Exp Neurol 2012; 238: 243-53.